SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients

Abstract We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1+ myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocyt...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lennard Ostendorf, Philipp Dittert, Robert Biesen, Ankelien Duchow, Victoria Stiglbauer, Klemens Ruprecht, Judith Bellmann-Strobl, Dominik Seelow, Werner Stenzel, Raluca A. Niesner, Anja E. Hauser, Friedemann Paul, Helena Radbruch
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9dbd84d824d44f7f9ebb0bb35db75826
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9dbd84d824d44f7f9ebb0bb35db75826
record_format	dspace
spelling	oai:doaj.org-article:9dbd84d824d44f7f9ebb0bb35db758262021-12-02T17:16:10ZSIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients10.1038/s41598-021-89786-02045-2322https://doaj.org/article/9dbd84d824d44f7f9ebb0bb35db758262021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89786-0https://doaj.org/toc/2045-2322Abstract We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1+ myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 86 MS patients, 41 NMOSD patients and 31 healthy controls. Additionally, we histologically evaluated the presence of SIGLEC1+ myeloid cells in acute and chronic MS brain lesions as well as other neurological diseases. We found elevated SIGLEC1 expression in 16/86 (18.6%) MS patients and 4/41 (9.8%) NMOSD patients. Almost all MS patients with high SIGLEC1 levels received exogenous interferon beta as an immunomodulatory treatment and only a small fraction of MS patients without interferon treatment had increased SIGLEC1 expression. In our cohort, SIGLEC1 expression on monocytes was—apart from those patients receiving interferon treatment—not significantly increased in patients with MS and NMOSD, nor were levels associated with more severe disease. SIGLEC1+ myeloid cells were abundantly present in active MS lesions as well as in a range of acute infectious and malignant diseases of the central nervous system, but not chronic MS lesions. The presence of SIGLEC1+ myeloid cells in brain lesions could be used to investigate the activity in an inflammatory CNS lesion.Lennard OstendorfPhilipp DittertRobert BiesenAnkelien DuchowVictoria StiglbauerKlemens RuprechtJudith Bellmann-StroblDominik SeelowWerner StenzelRaluca A. NiesnerAnja E. HauserFriedemann PaulHelena RadbruchNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Lennard Ostendorf Philipp Dittert Robert Biesen Ankelien Duchow Victoria Stiglbauer Klemens Ruprecht Judith Bellmann-Strobl Dominik Seelow Werner Stenzel Raluca A. Niesner Anja E. Hauser Friedemann Paul Helena Radbruch SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
description	Abstract We aimed to evaluate SIGLEC1 (CD169) as a biomarker in multiple sclerosis (MS) and Neuromyelitis optica spectrum disorder (NMOSD) and to evaluate the presence of SIGLEC1+ myeloid cells in demyelinating diseases. We performed flow cytometry-based measurements of SIGLEC1 expression on monocytes in 86 MS patients, 41 NMOSD patients and 31 healthy controls. Additionally, we histologically evaluated the presence of SIGLEC1+ myeloid cells in acute and chronic MS brain lesions as well as other neurological diseases. We found elevated SIGLEC1 expression in 16/86 (18.6%) MS patients and 4/41 (9.8%) NMOSD patients. Almost all MS patients with high SIGLEC1 levels received exogenous interferon beta as an immunomodulatory treatment and only a small fraction of MS patients without interferon treatment had increased SIGLEC1 expression. In our cohort, SIGLEC1 expression on monocytes was—apart from those patients receiving interferon treatment—not significantly increased in patients with MS and NMOSD, nor were levels associated with more severe disease. SIGLEC1+ myeloid cells were abundantly present in active MS lesions as well as in a range of acute infectious and malignant diseases of the central nervous system, but not chronic MS lesions. The presence of SIGLEC1+ myeloid cells in brain lesions could be used to investigate the activity in an inflammatory CNS lesion.
format	article
author	Lennard Ostendorf Philipp Dittert Robert Biesen Ankelien Duchow Victoria Stiglbauer Klemens Ruprecht Judith Bellmann-Strobl Dominik Seelow Werner Stenzel Raluca A. Niesner Anja E. Hauser Friedemann Paul Helena Radbruch
author_facet	Lennard Ostendorf Philipp Dittert Robert Biesen Ankelien Duchow Victoria Stiglbauer Klemens Ruprecht Judith Bellmann-Strobl Dominik Seelow Werner Stenzel Raluca A. Niesner Anja E. Hauser Friedemann Paul Helena Radbruch
author_sort	Lennard Ostendorf
title	SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
title_short	SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
title_full	SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
title_fullStr	SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
title_full_unstemmed	SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
title_sort	siglec1 (cd169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9dbd84d824d44f7f9ebb0bb35db75826
work_keys_str_mv	AT lennardostendorf siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT philippdittert siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT robertbiesen siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT ankelienduchow siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT victoriastiglbauer siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT klemensruprecht siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT judithbellmannstrobl siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT dominikseelow siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT wernerstenzel siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT ralucaaniesner siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT anjaehauser siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT friedemannpaul siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients AT helenaradbruch siglec1cd169amarkerofactiveneuroinflammationinthebrainbutnotinthebloodofmultiplesclerosispatients
_version_	1718381218111684608

SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients

Ejemplares similares